Gene expression profiling of di-n-butyl phthalate in normal human mammary epithelial cells

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 26, Issue 1, 2007, Pages 51-61

  Gwinn, Maureen R ^a   Whipkey, Diana L ^a   Tennant, Lora B ^a   Weston, Ainsley ^a  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Endocrine disruptors; Gene expression profiling; Human cell strains; Phthalate; Reproductive defects

Indexed keywords

DNA; GLUTATHIONE PEROXIDASE; INHIBIN; PHTHALIC ACID DIBUTYL ESTER; PLACENTAL GROWTH FACTOR; RNA; TUMOR NECROSIS FACTOR;

ARTICLE; BREAST CARCINOGENESIS; BREAST CELL; BREAST EPITHELIUM; BREAST REDUCTION; CELL STRAIN; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DNA HYBRIDIZATION; DNA MICROARRAY; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE INTERACTION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCTIVE TOXICITY; RNA ISOLATION; TISSUE SECTION;

EID: 34250797423     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvironPatholToxicolOncol.v26.i1.60     Document Type: Article

References (37)

1. The Breast Cancer Fund. Because We Are Worth It campaign for safe cosmetics. The Breast Cancer Fund; 2004.
2. Phthalate Information Center. Phthalates and Your Health. Phthalate Information Center; 2004.
3. EWG. Skin deep: A safety assessment of ingredients in personal care products. EWG; 2004.
4. Washam C. Baby ills from beauty aids? Environ Health Perspect. 2001;109(5):A202.
5. Cosmetic Ingredient Review Information. In: CIR, editor. http://www.cir-safety.org/staff_files/phthalates_summary.pdf; 2003.
6. FDA. FDA authority over cosmetics. US Food and Drug Administration; 1995.
7. FDA. Diethanolamine and cosmetic products. US Food and Drug Administration; 1999.
8. FDA. Prohibited ingredients and related safety issues. US Food and Drug Administration; 2000.
9. Patlak M. Hair Dye Dilemmas. US Food and Drug Administration; 1993.
10. Crews D, Willingham E, Skipper JK. Endocrine disruptors: present issues, future directions. Q Rev Biol. 2000;75(3):243-60.
11. Blount BC, Milgram KE, Silva MJ, Malek NA, Reidy JA, Needham LL, Brock JW. 2000a. Quantitative detection of eight phthalate metabolites in human urine using HPLC-APCI-MS/MS. Anal Chem. 72(17):4127-34.
12. Blount BC, Silva MJ, Caudill SP, Needham LL, Pirkle JL, Sampson EJ, Lucier GW, Jackson RJ, Brock JW. Levels of seven urinary phthalate metabolites in a human reference population. Environ Health Perspect. 2000;108(10):979-82.
13. Hauser R, Duty S, Godfrey-Bailey L, Antonia M. Medications as a source of human exposure to phthalates. Env Health Perspects. 2004;112:251-3.
14. Alonso-Magdalena P, Laribi O, Ropero AB, Fuentes E, Ripoll C, Soria B, Nadal A. Low doses of bisphenol A and diethylstilbestrol impair Ca2+ signals in pancreatic alpha-cells through a non-classical membrane estrogen receptor within intact islets of Langerhans. Environ Health Perspect. 2005;113(8):969-77.
15. Swan SH, Main KM, Liu F, Stewart SL, Kruse RL, Calafat AM, Mao CS, Redmon JB, Ternand CL, Sullivan S, et al. Decrease in anogenital distance among male infants with prenatal phthalate exposure. Environ Health Perspect. 2005;113(8):1056-61.
16. US Department of Health and Human Services. NTP-CERHR Expert panel report on Di-n-butyl phthalate. US Department of Health and Human Services; 2000. Report No.: NTP-CERHR-DBP-00.
17. Stampfer MR. Isolation and growth of human mammary epithelial cells. J Tissue Culture Methods. 1985;9:107-10.
18. Gwinn MR, Whipkey DL, Tennant LB, Weston A. Differential gene expression in normal human mammary epithelial cells treated with malathion monitored by DNA microarrays. Environ Health Perspect. 2005;113(8):1046-51.
19. Gwinn MR, Whipkey DL, Weston A. The effect of oxythioquinox exposure on normal human mammary epithelial cell gene expression: A microarray analysis study. Environ Health. 2004;3(1):9.
20. Khanna M, Qin KN, Klisak I, Belkin S, Sparkes RS, Cheng KC. Localization of multiple human dihydrodiol dehydrogenase (DDH1 and DDH2) and chlordecone reductase (CHDR) genes in chromosome 10 by the polymerase chain reaction and fluorescence in situ hybridization. Genomics. 1995;25(2):588-90.
21. Keshava C, Frye BL, Wolff MS, McCanlies EC, Weston A, Keshava N, Berkowitz GS, Brower S, Senie R, Bleiweiss IJ and others. Waf-1 (p21) and p53 polymorphisms in breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11(1):127-30.
22. EPA. Dibutyl phthalate (CASRN 84-74-2). Environmental Protection Agency; 1993.
23. Amstad PA, Krupitza G, Cerutti PA. 1992. Mechanism of c-fos induction by active oxygen. Cancer Res. 52(14):3952-60.
24. IARC. Occupational exposures of hairdressers and barbers and personal use of hair colorants. IARC; 1993.
25. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, Ecker J, Karumanchi SA. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab. 2004;89(2):770-5.
26. Suzumori N, Sugiura-Ogasawara M, Katano K, Suzumori K. Women with endometriosis have increased levels of placental growth factor in the peritoneal fluid compared with women with cystadenomas. Hum Reprod. 2003:18(12):2595-8.
27. Popovici RM, Kao LC, Giudice LC. Discovery of new inducible genes in in vitro decidualized human endometrial stromal cells using microarray technology. Endocrinology. 2000;141(9):3510-3.
28. Matzuk MM, Finegold MJ, Su JG, Hsueh AJ, Bradley A. Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature. 1992;360(6402):313-9.
29. Nelson KK, Schlondorff J, Blobel CP. Evidence for an interaction of the metalloprotease-disintegrin tumour necrosis factor alpha convertase (TACE) with mitotic arrest deficient 2 (MAD2), and of the metalloprotease-disintegrin MDC9 with a novel MAD2-related protein, MAD2beta. Biochem J. 1999;343(Pt 3):673-80.
30. Jeong SJ, Shin HJ, Kim SJ, Ha GH, Cho BI, Baek KH, Kim CM, Lee CW. Transcriptional abnormality of the hsMAD2 mitotic checkpoint gene is a potential link to hepatocellular carcinogenesis. Cancer Res. 2004;64(23):8666-73.
31. Li GQ, Zhang HF. Mad2 and p27 expression profiles in colorectal cancer and its clinical significance. World J Gastroenterol. 2004;10(21):3218-20.
32. Sze KM, Ching YP, Jin DY, Ng IO. Association of MAD2 expression with mitotic checkpoint competence in hepatoma cells. J Biomed Sci. 2004;11(6):920-7.
33. Kelly TL, Li E, Trasler JM. 5-aza-2′-deoxycytidine induces alterations in murine spermatogenesis and pregnancy outcome. J Androl. 2003;24(6):822-30.
34. DHHS. Reproductive genetics and epigenetics. DHHS; 2004.
35. Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis. 1996;17(6):1313-6.
36. Bersinger NA, Odegard RA. Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand. 2004;83(1):37-45.
37. Bersinger NA, Smarason AK, Muttukrishna S, Groome NP, Redman CW. Women with preeclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin A, activin A and soluble E-selectin. Hypertens Pregnancy. 2003; 22(1):45-55.